Annovis Bio, Inc. (ANVS) — 10-Q Filings

10-Q Filings (6)

• Annovis Bio Narrows Q3 Loss, Raises Capital Amid Going Concern Doubts — Nov 12, 2025 Risk: high
  Annovis Bio, Inc. reported a net loss of $7,262,658 for the three months ended September 30, 2025, a significant improvement from the $12,638,357 net loss in th
• Annovis Bio's Q2 Losses Widen Amid R&D Push — Aug 12, 2025 Risk: high
  Annovis Bio, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company posted a net loss
• Annovis Bio Files Q1 2025 10-Q — May 13, 2025 Risk: medium
  Annovis Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as QR Pharma, Inc., is in the pharmaceutical preparations ind
• Annovis Bio Q3 2024: Cash Dips to $105.2M — Nov 8, 2024 Risk: medium
  Annovis Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $105.2 million as of September 30,
• Annovis Bio Q2 2024 10-Q: Asset and Liability Update — Aug 14, 2024 Risk: medium
  Annovis Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $10,519,933 and total liabilities of $1,172,148. The
• Annovis Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — May 10, 2024 Risk: medium
  Annovis Bio, Inc. (ANVS) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Annovis Bio, Inc. filed a 10-Q report for the period ending March 31, 202

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX